This post refracts a PLOS ONE qualitative study through the lens of AI-enabled qualitative research to show how clinicians balance hyperkalaemia control and RAASi preservation. The primary keyword "qualitative analysis hyperkalaemia" guides a practical summary for qualitative researchers and clinical teams, with concrete numbers from the source and actionable ways AI tools speed synthesis and cross-segment insight.
Key Takeaways
The PLOS ONE study found that Spanish nephrologists prioritise preserving RAASi and view newer potassium binders as enablers of that strategy, while system-level access barriers limit consistent use (PLOS ONE).
- According to PLOS ONE (Gimenez-Stamminger et al., 2026), 12 nephrologists were interviewed in October 2025 and the study was published on July 30, 2026.
- According to PLOS ONE, 75% of participants had more than 15 years of clinical experience and interviews averaged 53 minutes per clinician.
- According to PLOS ONE, use in the prior 12 months was evenly split, with 50% of participants prescribing patiromer and 50% prescribing sodium zirconium cyclosilicate (SZC).
- According to PLOS ONE, clinicians described administrative restrictions such as visado and regional formularies as causes of delayed access and RAASi discontinuation.
What happened in the PLOS ONE study on hyperkalaemia?
The PLOS ONE study conducted semi-structured interviews with 12 practising nephrologists across six Spanish autonomous communities in October 2025 to explore clinical decision-making for predialysis CKD stages 3–5 (PLOS ONE).
According to PLOS ONE, interviews were transcribed verbatim, analysed in ATLAS.ti, and a team-developed codebook condensed 30 codes into 15 subthemes and five overarching themes.
According to PLOS ONE, participants reported a stepwise clinical algorithm: start with diet and diuretics, then bicarbonate or binders, and only as a last resort reduce or stop RAASi.
Direct participant perspectives in PLOS ONE included: "I structure the management in a stepped way: first line, diet and diuretics; second line, bicarbonate or binders; third line, reduction or suspension of drugs that increase potassium, as a last resort." (participant ID05 quoted in PLOS ONE).
Direct participant perspectives in PLOS ONE also included: "The arrival of the new binders has been a revolution. I have not had to dialyse patients urgently for hyperkalaemia for years, thanks to these treatments." (participant ID09 quoted in PLOS ONE).
Findings Snapshot
| Date | Metric | Value | Implication |
|---|---|---|---|
| October 2025 | Interviews completed | 12 nephrologists | Qualitative depth across six regions in Spain (PLOS ONE) |
| October 2025 | Mean interview length | 53 minutes | Sufficient time for detailed clinical narratives (PLOS ONE) |
| Past 12 months (reported) | Prescriber experience with newer binders | 50% patiromer / 50% SZC | Clinicians had contemporary prescribing experience with both agents (PLOS ONE) |
| July 30, 2026 | Publication date | PLOS ONE article published | Peer-reviewed dissemination of clinician perspectives (PLOS ONE) |
Implications for qualitative researchers and clinical teams
Answer: The study shows a replicable thematic structure that qualitative researchers can model when studying treatment access and clinician reasoning.
According to PLOS ONE, the five themes (stepwise management, newer binders as enablers, system-level barriers, patient engagement, and unmeasured HRQoL burden) provide a codebook-driven framework that other qualitative teams can adapt.
According to PLOS ONE, the finding that formal HRQoL assessment was infrequent suggests future qualitative and mixed-methods studies should integrate validated patient-reported measures, such as those recommended in the KDIGO 2024 guideline, to capture lived experience alongside biochemical control.
Answer: Clinicians and implementation researchers should treat administrative access rules as an explicit analytic node; PLOS ONE reports visado and regional formulary variation as concrete barriers that delay initiation of newer binders and may indirectly cause RAASi discontinuation.
How Evidano Helps
Problem: Long, manual synthesis of interview transcripts
Answer: Evidano reduces manual coding time by automating thematic extraction and frequency counts from interview transcripts.
Evidano is an AI-powered qualitative data analysis platform that helps researchers analyze interviews, open-ended surveys, and documents. Evidano ingests transcripts and produces code frequencies, co-occurrence networks, and hierarchical themes, which maps directly to the ATLAS.ti-style codebook workflow described in PLOS ONE.
Problem: Cross-segment comparisons (region, experience, binder use)
Answer: Evidano enables cross-segment analysis so teams can compare themes by clinician region, years of experience, or binder prescribing (the exact subgroups reported in PLOS ONE).
Evidano's thematic and cross-segment tools let researchers quantify how often themes like "visado barriers" or "nursing-led education" appear in specific participant groups, turning qualitative signals from studies like PLOS ONE into extractable evidence for policy briefs.
Problem: Preserving and sharing audit trails for rigour
Answer: Evidano maintains an auditable codebook history and supports team review to mirror the reflexive audit trail used in the PLOS ONE analysis.
Evidano records code definitions, merges, and coder comments so qualitative teams can reproduce the iterative codebook refinement that PLOS ONE describes.
Problem: Speeding stakeholder-ready outputs
Answer: Evidano exports concise tables, illustrative quotations, and visualizations ready for reports and policy meetings.
For teams wanting formatted deliverables like the PLOS ONE Table 2 style summaries, Evidano produces exportable tables and figures; learn more on the Evidano features page.
FAQ: qualitative analysis hyperkalaemia
What were the study methods and sample size?
Answer: The study used semi-structured interviews with 12 practising nephrologists across six Spanish regions conducted in October 2025, analysed using a codebook-based thematic approach (PLOS ONE).
According to PLOS ONE, interviews were transcribed verbatim, imported into ATLAS.ti, coded by multiple researchers, and consolidated into 30 codes, 15 subthemes, and five themes.
Did participants report that newer potassium binders change practice?
Answer: Yes, participants reported that patiromer and SZC improved tolerability and enabled continued RAASi use (PLOS ONE).
According to PLOS ONE, clinicians described newer binders as "revolutionary" for outpatient care and linked better tolerability to improved adherence and fewer emergency dialysis events.
What system-level barriers did the study identify?
Answer: The study identified visado prior authorisation, regional formulary variation, and fragmented cross-specialty communication as main barriers (PLOS ONE).
According to PLOS ONE, these administrative rules often delay access to newer binders and can result in RAASi suspension in acute settings without clear follow-up plans.
How should future qualitative or mixed-methods research build on these findings?
Answer: Future work should combine clinician interviews with patient-reported outcome measures and prescribing/payer data to test whether reported barriers translate into measurable care gaps (PLOS ONE).
According to PLOS ONE, integrating PROMs and real-world prescribing datasets would address the current evidence gap between clinician intent and measured outcomes.
How can AI-assisted qualitative tools be used ethically in health research?
Answer: Use AI tools to accelerate coding and synthesis while preserving participant confidentiality, human oversight, and documented audit trails.
According to best-practice guidance echoed by the PLOS ONE authors, transcripts should be pseudonymised, data access restricted, and AI outputs reviewed by experienced qualitative researchers before dissemination.
Conclusion & Next Steps
The PLOS ONE qualitative analysis (Gimenez-Stamminger et al., 2026) shows clinicians prioritise RAASi preservation and see newer potassium binders as clinically enabling, but they face persistent administrative and coordination barriers.
For qualitative teams and clinical researchers, the study supplies a ready-made codebook structure and concrete themes to test in larger mixed-methods or implementation studies.
If you want to speed transcript synthesis, quantify theme frequencies, and produce stakeholder-ready tables like those in PLOS ONE, consider AI-assisted tools that preserve audit trails and human oversight.
To try an AI platform designed for qualitative health research, Try Evidano for free.